Introduction
High-dose (hd) chemotherapy with autologous stem cell transplantation (ASCT) is an effective treatment option for most chemosensitive tumors, particularly Hodgkin's and non-Hodgkin's lymphoma. 1 Its toxicity has been markedly lowered by the transplantation of peripheral blood progenitor cells (PBPC). [2] [3] [4] PBPC collection and administration are simple and feasible, and result in fast postgraft recovery and consequently low treatmentrelated mortality. Extensive use of a highly tolerable intensive approach has improved the survival expectancy of many highrisk lymphoma patients. 5, 6 However, the prolongation of survival has been accompanied by an increased risk of developing secondary hematological neoplasms, compared with age-matched controls. [7] [8] [9] [10] [11] DNA damage induced by mutagenic agents and the proliferative stress associated with bone marrow repopulation are considered to play major roles in the pathogenesis of these complications. 12, 13 Recent observations have focused on the role of telomeres in the pathogenesis of post-transplant hematological neoplasms.
Telomeres are linear DNA structures situated at the ends of chromosomes that help to maintain genome stability by preventing degradation, recombination and fusion of doublestranded DNA ends. [14] [15] [16] In the absence of effective telomereprotecting mechanisms, chromosomes lose 50-200 base pairs (bp) of their telomere sequences at each mitotic division. Progressive telomere shortening leads to senescence, a peculiar phase of cell life, chiefly characterized by growth inhibition. [17] [18] [19] [20] Senescence may ultimately progress to crisis, entailing genetic instability, chromosomal fusions and a high propensity to apoptotic death or malignant transformation. 21, 22 In germ line and in some somatic cells, telomere length (TL) is maintained by various DNA-elongating mechanisms, in particular the RNA-dependent telomerase. 17, 20, 23, 24 Despite the ability of immature hemopoietic cells to activate telomerase, the TL of both early and committed progenitors progressively shortens with age, as in other highly replicating tissues. [25] [26] [27] [28] This suggests either that the mechanisms for telomere maintenance become less effective with age in stem and progenitor cells, or that replicative stresses increase in intensity throughout cell life and induce extensive telomere shortening that cannot be sufficiently offset by DNA elongation. 29 Considerable and potentially stressful proliferative effort is required from hematopoietic cells following chemotherapy, particularly if delivered at high doses. This abnormal proliferation is even more pronounced during marrow regeneration after autologous or allogeneic transplantation, and several reports have shown marked though variable telomere shortening in transplanted patients. [30] [31] [32] [33] Increased susceptibility to genetic damage associated with reduced TL could be crucial in the development of secondary myelodysplastic syndromes and leukemia after transplantation.
Less is known about the telomere structure of the BM or PBPC harvests employed in transplant procedures. This information would be of particular value in the autograft setting, since harvesting is frequently scheduled after a variable number of chemotherapy courses. We evaluated the TL of PBPC collected in a hd-sequential chemotherapy program (HDS) designed for highrisk lymphoma. The program includes two consecutive courses of PBPC mobilization, after hd-cyclophosphamide (CY) and hd-Ara-C, delivered at approximately 1 month interval. 34 The aims of the study were (i) to see whether the tightly spaced administration of hd drugs results in detectable telomere shortening; (ii) to see whether in vitro clonogenic assays predict changes in the TL of hemopoietic progenitors; (iii) to define the value of telomere evaluation on PBPC employed in ASCT programs.
Patients and methods

Patients and treatment schedule
TL was assessed in PBPC from 37 previously untreated patients aged o60 years, undergoing an HDS program for advanced-stage, aggressive NHL. Their median age was 45 years (range 18-59), 15 were female and 22 male subjects, histologic diagnosis included: diffuse large-cell lymphoma (27) , mantlecell lymphoma (6) and non-B-cell aggressive lymphoma (4) . All patients presented with advanced-stage disease and most had unfavorable prognosis at presentation.
The chemotherapy regimen consisted of an intensive debulking phase with two courses of PBPC mobilization and harvest, followed by myeloablative treatment with PBPC autograft. 34 All patients started with three APO courses (75 mg/ m 2 doxorubicin þ 1.4 mg/m 2 vincristine on days þ 1, þ 15, þ 22 plus 1 mg/kg prednisone daily on days . The subsequent hd phase comprised the sequential administration with a 20-25 day interval of (i) 7 gr/m 2 CY; (ii) 2 g/m 2 hd-Ara-C administered over 2 h every 12 h for a total of 12 doses; (iii) 2.4 g/m 2 hd-etoposide (VP16) þ 100 mg/m 2 cisplatin, starting 16 h after VP16. G-CSF was given at 5 mg/kg/day after each course until ANC recovery or completion of PBPC harvest. Each course was started when ANC was 41000/ml and PLTS were 4100 000/ml. PBPC collections were scheduled following hd-CY and following hd-Ara-C. To predict the optimal timing of leukapheresis, circulating CD34 þ cells and cell blood counts were evaluated daily starting from day þ 9 until the end of harvesting. An aliquot of PBPC collected following CY (1-2 Â 10 6 CD34 þ cells/kg) was reinfused the day after the last Ara-C dose to minimize hematological toxicity. Figure 1 shows the PBPC collection and reinfusion scheme. The final myeloablative phase consisted of 60 mg/m 2 mitoxantrone and 180 mg/m 2 L-PAM given i.v. on days À5 and À2, respectively; PBPC were reinfused on day 0, as detailed elsewhere. 35 G-CSF was given at 5 mg/kg/day following autograft until ANC recovery. 36 All patients were part of prospective study protocols approved by our institutional Ethical Committee, and gave written informed consent.
Circulating CD34 þ cell evaluation and collection
Circulating and harvested progenitors were determined by evaluating CD34 þ cells on whole blood as well as on leukapheresis specimens by flow cytometry with an anti-CD34 monoclonal antibody (MoAb) QBEND10 (Serotec, Oxford, UK) directly conjugated to the fluorocrome phycoerythrin (PE) as detailed elsewhere. 34 The frequency of CD34 þ cells was calculated as the percentage of all viable cells. The number of circulating CD34 þ cells was obtained by multiplying this percentage by the total number of leukocytes in 1 ml of blood; the total number of CD34 þ cells ( Â 10 6 /kg) in leukapheresis yields was calculated by multiplying CD34 þ percentage by the total number of leukocytes collected, and dividing by body weight.
Peripheral blood buffy-coat cells were collected when the WBC count was at least 1000/ml and PB CD34 þ cells 420/ml. Leukapheresis was performed with continuous-flow blood cell separators (COBE-SPECTRA or FRESENIUS). From 7 to 13 l blood (median 8.9 l) was processed in each procedure.
In vitro functional evaluation of harvested PBPC Circulating hemopoietic progenitor frequency was evaluated by plating total peripheral blood leukocytes obtained after RBC sedimentation in the presence of 33% Emagel (Behring). 34 The analysis was also performed on cells from both leukapheresis products by plating in semisolid medium 1, 10 and 100 ml of the buffy coat obtained from leukapheresis cell suspension, with no additional cell separation to avoid progenitor cell enrichment.
In a group of patients for whom cryopreserved leukapheresis samples obtained following hd-CY and hd-Ara-C were available, the in vitro growth of both committed (CFU-GM) and primitive LTC-IC progenitors was concomitantly evaluated. 37 The CFU-GM assay was carried out as described elsewhere. Briefly, 1-5 Â 10 4 nucleated cells were plated in 35-mm Petri dishes in methylcellulose-based medium (HCC-4100; Stem Cell Technologies, Vancouver, Canada) supplemented with rhSCF, rhIL-3, rhG-CSF and rhGM-CSF (Stem Cell Technologies). Progenitor cell growth was evaluated after 14-18 days of incubation. The long-term culture-initiating cell (LTC-IC) assay was performed as has been previously described. [38] [39] [40] Briefly, test cells were resuspended in complete medium consisting of alpha-medium (Cambrex, Verviers, Belgium, EU) supplemented with 12.5% fetal bovine serum and 12.5% horse serum (Stem Cell Technologies), L-glutamine (2 mM), 2-mercaptoethanol Telomere shortening in mobilized PBPC I Ricca et al Diagnostic Mannheim, Germany) and UV crosslinked for 10 min. Hybridization was carried out with the TeloTAGG Telomere Length Assay Kit (Roche Diagnostics, Manheim, Germany). Membranes were hybridized for 3 h with 2 ml of the digoxigenin (DIG)-labeled probe specific for telomeric repeats. Filters were then washed and incubated with a DIG-specific antibody covalently coupled to alkaline phosphate (AP). Results were visualized using AP metabolizing CDP-Star, a highly sensitive chemiluminescent substrate. The light signal was recorded on X-ray film (Lumi-Film Chemiluminescent Detection Film, Roche Diagnostic, Mannheim, Germany), then scanned and analyzed using KODAK DIGITAL SCIENCE T M 1D Image Analysis Software (Molecular Dynamics). The highest concentration of telomeric repeats ('peak TRF length') was evaluated. In most cases, the 'mean TRF length' was also calculated following a method described in the literature. 41, 42 Analogous results were obtained with the two calculation methods.
In order to assess the validity of the method used, TL was evaluated on mononuclear cells from healthy volunteers representative of the general population. PB was obtained from 60 normal subjects, aged 14-91 years. Anonymity was maintained: each individual was identified by a personal barcode and only sex and date of birth were known. Progressive shortening of telomere sequences with aging was observed, in line with the well-established correlation. 17, 19 Our age-related telomere-shortening curve is shown in Figure 2 ; we estimated a shortening rate of about 50 bp/year.
Isolation of CD34 þ cells
To evaluate TL on highly purified progenitor cells, experiments were performed on purified CD34 þ cell populations. CD34 þ cells were purified from leukaphereses of 12 patients using the CD34 Isolation Kit, MACS MS and LS separation columns, and a VarioMACS magnetic cell separator (Miltenyi Biotec, Bergisch Gladbach, Germany), as reported elsewhere. 43 Mononuclear cells were incubated with 100 ml FcR Blocking Reagent (human immunoglobulin) and 100 ml of the Hapten Antibody (antimouse IgG1 monoclonal CD34 þ antibody) for 15 min at 41C. Cells were washed, resuspended in 400 ml buffer and incubated with 100 ml Anti-Hapten Microbeads for 15 min at 41C. The cell suspension was then loaded onto the column and negative cells were allowed to pass through. The column was washed, removed from the separator, and the bound cells were flushed out. The whole separation procedure was repeated twice. The recovered CD34 þ cells were determined by cytofluorescence assay, as described above.
Results
Hemopoietic progenitor cell mobilization and collection
All 37 patients showed high progenitor cell mobilization after both hd-chemotherapy courses. The median peak values of circulating CD34 þ cells/ml were 256 (range 9-939) and 182 (range 5-914), after hd-CY and hd-Ara-C, respectively (P ¼ 0.36). Peak circulating CFU-GM/ml was also high after hd-CY (median 16 Â 10 3 /ml, range 3-93) and hd-Ara-C (median 14 Â 10 3 /ml, range 1-71), without significant differences (P ¼ 0.44).
Large amounts of hemopoietic progenitors (CD34 þ cells and CFU-GM/kg) were collected in all cases after both courses, in line with our previous report. 34 There were no significant between-course differences and, as detailed in Figure 3a Table 1 , all samples tested contained variable amounts of LTC-IC progenitors. The frequency of both early and late progenitors was similar in leukaphereses after hd-CY and after hd-Ara-C.
TL analysis on harvest products
TL was evaluated by determining TRF on mononuclear cell suspensions from harvest products obtained after hd-CY and hdAra-C. As shown in Figure 4 , there was a marked shortening, with median TRF of 8242 bp (range 4895-14 860) after hd-CY and 7226 bp (range 4135-9852) after hd-Ara-C (Po0.0001). A longer telomere following hd-CY vs hd-Ara-C was observed in all but one patient. The median telomere shortening after completion of the two courses corresponds approximately to the decrease occurring in normal subjects after 20 years of life, on our curve.
TL analysis on purified CD34 þ cells
To rule out the possibility that length differences might reflect differences in the content of progenitor cells in the leukaphereses, TRF was evaluated on purified CD34 þ cell populations. CD34 þ cells from post-CY and post-Ara-C leukaphereses of 12 patients were purified using the Miltenyi miniMACS device. As shown in Figure 5 , cell populations highly selected for progenitor cells were obtained, with CD34 þ values between 55 and 98%. Once again, a significant difference in TL was observed between post-CY and post-Ara-C cells. Indeed, in all 12 cases, purified CD34 þ cells from post-Ara-C harvests consistently displayed a shorter telomere.
Changes of TL throughout intensive chemotherapy and autograft
In order to evaluate whether TL might be shortened by exposure to the debulking chemotherapy and hd-CY, on 12 patients it was assessed on pretreatment BM cells and on post-CY PBPC. No significant difference in TL between pretreatment samples (7913; range: 6060-9823) and harvested PBPC (8256; range: 6106-10 108) was found (P ¼ 0.18). Similarly, TL was compared between grafted PBPC and BM samples taken at a median follow-up of 48 months. (Range 6-66 months) after autograft. A slight decrease in TL occurred in postautogarft samples (7199; range: 5769-8690) compared to grafted PBPC (7396; range: 6123-8906); however, the difference did not achieve statistical significance (P ¼ 0.07). No major differences were observed in postgraft TL shortening depending on the type of graft, that is, post-CY or post-Ara-C.
Long-term engraftment of post-CY and post-Ara-C PBPC
Hemopoietic reconstitution was monitored in 30 patients undergoing autograft and evaluable for at least 12 months thereafter. A total of 12 patients received post-CY PBPC and 18 patients post-Ara-C PBPC. The number of grafted CD34 þ cells was similar in the two groups (post-CY group: median 7.8 Â 10 6 CD34/kg, range 4-30; post-Ara-C group: median 7.8 Â 10 6 CD34/kg, range 4-23, P ¼ 0.75). Engraftment occurred in all cases. As shown in Table 2 , WBCs and hemoglobin values Table 1 Comparison of the frequency of hemopoietic progenitors in leukaphereses obtained after cyclophosphamide and after Ara-C from 10 representative patients The frequency of hemopoietic progenitors was evaluated on thawed nucleated cells obtained from leukaphereses performed after hdcyclophosphamide (post-CY) and hd-Ara-C (post-Ara-C). Telomere shortening in mobilized PBPC I Ricca et al recorded at 1, 3, 6 and 12 months after autograft were substantially similar in the two groups. On the contrary, platelet recovery was significantly delayed in the post-Ara-C group compared to the post-CY group, by as much as 6 months after autograft. Thereafter, platelets slowly increased in the post-ARA-C group and differences in platelet values were no longer significant 1 year after autograft.
Discussion
The study evaluated the TL of PBPC harvested following two consecutive mobilization procedures performed with high-dose chemotherapy and G-CSF. The results indicate that despite the analogous amounts of harvested progenitors, TL was significantly shorter in PBPC collected after the second mobilizing course. A single hd course delivered soon after a previous course induced an overall shortening analogous to that observed after approximately 20 years of life. Nevertheless, no qualitative changes in terms of in vitro growth capacity were observed. Thus, TL analysis should be considered whenever a thorough evaluation of PBPC functional characteristics is required.
The occurrence of marked though variable telomere shortening following autologous and allogeneic transplantation is well known. [30] [31] [32] [33] Less is known about the TL of PBPC harvests, and the relationship between TL and timing of PBPC collection has never been investigated. We addressed this question during the development of a new sequential hd schedule comprising two consecutive PBPC harvests following hd-CY and hd-Ara-C. Small aliquots of post-CY CD34 þ cells were reinfused following hd-Ara-C to reduce hematological toxicity. The scheme was originally designed to improve conditions for adequate PBPC collection. Indeed, we recently reported that large quantities of PBPC can be collected following hd-Ara-C in both high and poor mobilizer patients. 34 In addition, the combination of Rituximab with repeated chemotherapy administrations had an in vivo purging effect, as demonstrated by the high frequency of PCR-negative harvests following hd-Ara-C observed in mantle-cell and relapsed follicular lymphoma patients. 44 , 45 Reduction of tumor contamination might explain the preferential use of PBPC collected after repeated chemotherapy courses. Our patient group was uniform: age o60 years, advancedstage disease and no previous treatment. None of them had bone marrow involvement. Thus, they did not present with major impairment of the hematopoietic function. All patients showed high values of circulating progenitors following each of the two mobilization courses and thus displayed all the prerequisites for proper evaluation of hemopoietic progenitor cell senescence following hd chemotherapy. We also elaborated an age-related telomere shortening curve from a healthy population. The relationship between TL and age was clear, and each decade of life was found to be associated with telomere shortening of approximately 500 bp, in line with other reports. 19, 25 Despite the massive PBPC mobilization, cells harvested at the second mobilization showed marked telomeric loss compared to those collected at the first mobilization. The influence of chemotherapy on TL has been demonstrated in patients after multiple chemotherapy courses with or without stem cell autografting. 31, 32 Here, we show that significant telomere loss takes place after a single hd course. The cost, in terms of telomere loss, of delivering hd-Ara-C corresponded to that normally paid in approximately 20 years of life in the absence of nonphysiologic hematopoietic stress. It may be that telomere erosion is only induced by hd-Ara-C and not by other drugs. However, preliminary observations suggest that a similar shortening pattern occurs if hd-VP16 is given after hd-CY (I Ricca, unpublished observation). Thus, timing of PBPC harvesting seems to be a critical factor to reduce the risk of autografting progenitor cells with marked telomere erosion. This is of clinical relevance since it is well known that short telomeres result in genomic instability and favor malignant transformation. 13, 18, 22 In order to verify whether telomere shortening was caused by the administration of chemotherapy at high doses, TL was evaluated on pretreatment BM cells and compared to that of post-CY PBPC; no significant change in length was found. Thus, the marked TL shortening observed in PBPC collections following hd-ARA-C is likely due to the high proliferative stress of hemopoietic progenitors undergoing two tightly spaced post-CY post-Ara-C
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Telomere length (bp) Telomere shortening in mobilized PBPC I Ricca et al chemotherapy courses with G-CSF, rather than to the administration of high-dose chemotherapy per se. A further though slight telomere erosion was observed in postautograft BM samples compared to grafted PBPC. The extent of postautograft telomere erosion was not influenced by the type of graft, that is, post-CY or post-Ara-C PBPC. This indicates that differences in TL between post-CY and post-Ara-C PBPC were maintained after autograft. Very recently, it has been reported that the occurrence of secondary myelodysplastic syndromes and acute leukemia following autograft is strongly influenced by the type and intensity of previous chemotherapy treatment. 46 No significant correlation has been observed with the type of conditioning regimen employed, while a trend toward a higher incidence of secondary myelodysplasia has been found with the use of PBPC compared to BM cells. Based on our study, prolonged treatments with specific cytotoxic drugs may be presumed to induce telomere erosion of hemopoietic progenitor cells. When mobilized and reinfused during autograft, these cells may undergo further telomere loss and set the stage for the onset of malignant clones. The observation that the shortened telomere of grafted post-Ara-C PBPC was maintained without major modifications following autograft further strengthens this hypothesis.
Telomerase is activated in progenitor cells exposed either in vitro or in vivo to G-CSF. 47, 48 Mobilization with G-CSF induces increased telomerase activity in BM, and even more so in PBmobilized CD34 þ cells. A similar enzymatic activation occurs when G-CSF is given to patients receiving CHOP chemotherapy, and it appears to prevent or attenuate telomere loss associated with chemotherapy. In our program, G-CSF support was given to all patients following both hd-CY and hd-Ara-C. Our observation of telomere shortening in post-Ara-C PB cells suggests that telomerase activation by G-CSF is not enough to counteract the marked telomere erosion induced by hd courses given at short intervals. Furthermore, the use of progenitor cells characterized by reduced TL along with G-CSF-induced telomerase activation might be particularly harmful. Indeed, the combination of short telomeres with high telomerase activity has been shown to predispose mammalian cells to neoplastic transformation. [49] [50] [51] [52] Telomerase activation following proliferative stress has been found in hematopoietic stem cells and in their immediate progeny, whereas it is not detectable in nonproliferating, differentiated cells. 27, 28, 47 Early progenitors may thus have a reduced rate of telomere loss and one could argue that differences in TL between post-CY and post-Ara-C harvests simply reflect different early progenitor concentrations. However, this is ruled out by the finding that the pattern of telomere loss could be reproduced on purified populations of CD34 þ cells. Early progenitors were then assessed for their in vitro growth capacity, and no difference was found in terms of CFU-GM and LTC-IC growth between post-CY and post-Ara-C progenitor cells. This suggests that differences in TL of progenitor cells cannot be identified by means of commonly employed in vitro growth assays.
Post-CY and post-Ara-C progenitors had similar behavior both in vitro and in vivo. They were separately employed for autografting in two groups of patients: leukocyte recovery was fast in both groups, whereas platelet values recovered significantly more slowly with post-Ara-C compared to post-CY PBPC. It cannot as yet be determined whether post-Ara-C telomere loss selectively occurred in highly proliferating progenitor cells without affecting quiescent primitive hematopoietic stem cells, or whether these dormant cells may have also been recruited into the cell cycle after hd chemotherapy with a consequent Table 2 Hematologic recovery in two groups of patients autografted with PBPC collected after hd-CY or hd-Ara-C Telomere shortening in mobilized PBPC I Ricca et al telomere loss during proliferation. The delay in platelet recovery may thus reflect a transient impairment of the committed progenitors responsible for early postgraft recovery. Alternatively, the finding might be an early manifestation of a reduced engraftment capacity of both committed and primitive hemopoietic stem cells. Indeed, late graft failure has been reported to be associated with marked telomere shortening following autograft. 53 A prolonged follow-up of our series will show whether telomere shortening of PBPC employed in autografting procedures affects their long-term engraftment capacity.
In conclusion, our study demonstrates that PBPC undergo a marked telomere loss after two hd chemotherapy courses with G-CSF separated by a 1-month interval. This short interval is responsible for the telomere loss, though hd-Ara-C may have somehow influenced telomere stability. Telomere loss was not associated with quantitative or qualitative defects of the harvested progenitor cells; telomere evaluation thus appears advisable whenever new mobilization procedures, including the use of hd chemotherapy and/or novel cytokines, are being elaborated. We now employ post-Ara-C PBPC for autografting solely in patients with poor mobilization or evidence of tumor contamination at post-CY harvesting. In all other situations, we prefer to use post-CY PBPC. Finally, the availability of early progenitors with marked differences in TL will help to illustrate the relationship between telomere and hemopoietic cell survival. Experiments are now in progress to evaluate long-term hematopoiesis in NOD/SCID mice injected with the two types of hemopoietic progenitor cells, and will clarify whether cell senescence associated with telomere shortening also affects primitive hematopoietic stem cells and reduces their long-term survival and engraftment capacity.
